This report was prepared in order to comply with the Belgian Royal Decree of November 14, 2007. You can also find this information on the website of ThromboGenics (www.thrombogenics.com) in the Investor Information section.

ThromboGenics published its Interim Financial Report in Dutch. In the case of differences of interpretation between the English and the Dutch versions of the Report, the original Dutch version prevails.

Interim Financial Report
Half-year results as of June 30, 2018

Consolidated key figures as of June 30, 2018

Unaudited consolidated statement of financial position

In '000 euro	June 30, 2018	December 31, 2017
Property, plant and equipment	764	991
Intangible assets	22,027	23,603
Other non-current assets	127	126
Non-current tax credit	2,325	1,434
Inventories	2,143	2,204
Trade and other receivables	3,729	4,295
Current tax receivables	2,048	2,054
Investments	25,640	49,555
Cash and cash equivalents	75,793	56,175
Restricted cash	0	10,000
Total assets	**134,596**	**150,437**
Total equity	128,076	133,357
Current liabilities	6,520	17,080
Total equity and liabilities	**134,596**	**150,437**

Unaudited consolidated statement of profit and loss

In '000 euro (for the period ended on June 30)	**2018**	**2017**
Income	**3,752**	**2,746**
Operating result	**-15,664**	**-15,012**
Finance income	571	67
Finance expense	-74	-273
Result before income tax	**-15,167**	**-15,218**
Income tax expense	-4	-3
Loss of the period	**-15,171**	**-15,221**
Result per share		
Basic earnings/(loss) per share (euro)	-0.39	-0.42
Diluted earnings/(loss) per share (euro)	-0.39	-0.42

A full analysis of the interim financial statements, prepared in accordance with IAS 34, as declared applicable by the European Union, is included under the section “Condensed consolidated interim financial statements”.

These statements were submitted to a review by the statutory auditor.

Highlights

Following shareholders’ approval at an EGM held on September 3, 2018, and effective as of September 10, 2018, ThromboGenics NV is changing its corporate name to Oxurion NV. The new name Oxurion is designed to better reflect the company’s ambition to deliver best in class therapies for back of the eye disorders, following recent progress made with the company’s innovative diabetic eye disease pipeline.

Pipeline

- Positive Day 90 topline results reported from Phase 1/2 clinical study evaluating THR-317 (anti-PlGF) for the Treatment of Diabetic Macular Edema (DME). Day 150 topline results reported in July 2018 reinforced the positive Day 90 results by confirming safety and tolerability and indicated durability of clinical activity.

- First patient enrolled in Phase 2 clinical study evaluating the efficacy and safety of intravitreal THR-317 (anti-PlGF) administered in combination with Lucentis® (ranibizumab, anti-VEGF) for the treatment of diabetic macular edema (DME), including treatment resistant patients.



- First patient enrolled in a Phase 1 clinical study (THR-149-001) evaluating the safety of THR-149 (plasma kallikrein inhibitor) for the treatment of DME.

- THR-687 (integrin antagonist), under development for the treatment of diabetic retinopathy (DR) and/or DME), is expected to enter a Phase 1 clinical study in Q3 2018.

- Oncurious Phase 1/2a study with TB-403 for medulloblastoma: evaluation of 3rd (out of 4) dose level is running towards endpoint. Initial data by mid-2019 with progress update in Q1 2019.

Financial

- On 26th January 2018, the completion of an equity investment of €10 million by Novartis Pharma AG in ThromboGenics' capital was confirmed.

- In H1 2018, ThromboGenics reported overall revenues of €3.8 million from JETREA®, compared to €2.7 million as of June 30, 2017.

- Cash and cash equivalents and investments were €101.4 million as of the end of June 2018. This compared to €115.7 million as of 31st December 2017. Both figures include the €10 million equity investment received from Novartis Pharma AG. It was accounted for as restricted cash in ThromboGenics' accounts as of 31st December 2017 and became unrestricted on the completion date of 26 January 2018.



Condensed consolidated interim financial statements

Unaudited consolidated statement of profit and loss

In '000 euro (for the period ended on June 30)	**2018**	**2017**
Income	**3,752**	**2,746**
Sales	3,750	1,886
Income from royalties	2	860
Cost of sales	**-1,117**	**-1,996**
Gross profit	**2,635**	**750**
Research and development expenses	-13,349	-10,544
General and administrative expenses	-2,874	-3,176
Selling expenses	-2,541	-2,062
Other operating income	465	20
Operating result	**-15,664**	**-15,012**
Finance income	571	67
Finance expense	-74	-273
Result before income tax	**-15,167**	**-15,218**
Taxes	-4	-3
Loss of the period	**-15,171**	**-15,221**
Attributable to:		
Equity holders of the company	-15,028	-15,214
Non-controlling interest	-143	-7
Result per share		
Basic earnings/(loss) per share (euro)	-0.39	-0.42
Diluted earnings/(loss) per share (euro)	-0.39	-0.42

Unaudited consolidated statements of other comprehensive income

In '000 euro (for the period ended on June 30)	**2018**	**2017**
Loss of the period	**-15,171**	**-15,221**
Exchange differences on translation of foreign operations	-58	7
Other comprehensive income, net of income tax	**-58**	**7**
Other comprehensive income that will not be reclassified to profit or loss	-58	7
Total comprehensive income for the period	**-15,229**	**-15,214**
Attributable to:		
Equity holders of the company	**-15,086**	**-15,207**
Non-controlling interest	**-143**	**-7**



ThromboGenics®
Advancing Science. Enhancing Vision.®

Unaudited consolidated statement of financial position

In '000 euro	June 30, 2018	December 31, 2017
ASSETS		
Property, plant and equipment	764	991
Intangible assets	22,027	23,603
Other non-current assets	127	126
Non-current tax credit	2,325	1,434
Non-current assets	**25,243**	**26,154**
Inventories	2,143	2,204
Trade and other receivables	3,729	4,295
Current tax receivables	2,048	2,054
Investments	25,640	49,555
Cash and cash equivalents	75,793	56,175
Restricted cash	0	10,000
Current assets	**109,353**	**124,283**
Total assets	**134,596**	**150,437**
EQUITY AND LIABILITIES		
Share capital	137,485	151,991
Share premium	0	157,661
Cumulative translation differences	-393	-335
Other reserves	-13,193	-13,141
Retained earnings	3,593	-163,546
Equity attributable to equity holders of the company	**127,492**	**132,630**
Non-controlling interest	584	727
Total equity	**128,076**	**133,357**
Trade payables	3,850	3,298
Other short-term liabilities	2,670	13,782
Current liabilities	**6,520**	**17,080**
Total equity and liabilities	**134,596**	**150,437**



ThromboGenics®
Advancing Science. Enhancing Vision.®

Unaudited consolidated statement of cash flows

In '000 euro (for the period ended on June 30)	**2018**	**2017**
Cash flows from operating activities		
Loss of the period	-15,171	-15,221
Finance expense	74	273
Finance income	-571	-67
Depreciation on property, plant and equipment	256	379
Amortization of intangible assets	1,577	1,579
Equity settled share-based payment transactions	-52	88
Change in trade and other receivables including tax receivables and inventories	-258	1,756
Change in short-term liabilities	-10,560	-3,469
Net cash (used) from operating activities	***-24,706***	***-14,682***
Cash flows from investing activities		
Disposal of property, plant and equipment (following a sale)	58	48
Change in investments	23,915	97
Interest received and similar income	90	10
Acquisition of property, plant and equipment	-88	-139
Acquisition (divestments) of other non-current assets	-1	41
Net cash (used in) generated by investing activities	***23,974***	***57***
Cash flows from financing activities		
Proceeds from issue of share capital	10,000	0
Paid interests	-4	-5
Net cash (used in) generated by financing activities	***9,996***	***-5***
Net change in cash and cash equivalents	**9,265**	**-14,630**
Cash and cash equivalents at the start of the period	66,175	58,251
Effect of exchange rate fluctuations	353	-204
Cash and cash equivalents at the end of the period	**75,793**	**43,417**



ThromboGenics
Advancing Science. Enhancing Vision.

Unaudited consolidated statement of changes in equity

	Share capital	Share premium	Cumulative translation differences	Other reserves	Retained earnings	Attributable to equity holders of the company	Non-controlling interest	Total
Balance as at January 1, 2017	**151,991**	**157,661**	**-185**	**-13,317**	**-186,334**	**109,816**	**43**	**109,859**
Loss of the period 2017	0	0	0	0	-15,214	-15,214	-7	**-15,221**
Change to foreign currency translation difference and revaluation reserve	0	0	7	0	0	**7**	**0**	**7**
Share-based payment transactions	0	0	0	88	0	**88**	**0**	**88**
Balance as at June 30, 2017	**151,991**	**157,661**	**-178**	**-13,229**	**-201,548**	**94,697**	**36**	**94,733**

Balance as at January 1, 2018	**151,991**	**157,661**	**-335**	**-13,141**	**-163,546**	**132,630**	**727**	**133,357**
Loss of the period 2018	0	0	0	0	-15,028	**-15,028**	**-143**	**-15,171**
Change to foreign currency translation difference and revaluation reserve	0	0	-58	0	0	**-58**	**0**	**-58**
Capital increase	9,796	204	0	0	0	**10,000**	**0**	**10,000**
Capital decrease	-24,302	-157,865	0	0	182,167	**0**	0	**0**
Share-based payment transactions	0	0	0	-52	0	**-52**	**0**	**-52**
Balance as at June 30, 2018	**137,485**	**0**	**-393**	**-13,193**	**3,593**	**127,492**	**584**	**128,076**

Statutory auditor's report to the Board of Directors of ThromboGenics NV on the review of consolidated interim financial information for the six-month period ended 30 June 2018

Introduction

We have reviewed the accompanying interim consolidated statement of financial position of ThromboGenics NV as of 30 June 2018 and the related interim consolidated statements of comprehensive income, cash flows and changes in equity for the six-month period then ended, as well as the explanatory notes. The Board of Directors is responsible for the preparation and presentation of this consolidated interim financial information in accordance with IAS 34 "Interim Financial Reporting", as adopted by the European Union. Our responsibility is to express a conclusion on this consolidated interim financial information based on our review.

Scope of review

We conducted our review in accordance with International Standard on Review Engagements 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity". A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying consolidated interim financial information is not prepared, in all material respects, in accordance with IAS 34 "Interim Financial Reporting", as adopted by the European Union.

Zaventem, 6 September 2018

BDO Bedrijfsrevisoren Burg. Ven. CBVA / BDO Réviseurs d'Entreprises Soc. Civ. SCRL
Statutory auditor
Represented by Gert Claes

Notes to the condensed consolidated interim financial statements

1. Summary of significant accounting policies and main accounting estimates and assessments

1.1. Basis of preparation of half-year report

This condensed consolidated interim financial information has been prepared in accordance with IAS 34, (Interim Financial Reporting) as adopted by the European Union.

These condensed interim consolidated financial statements of ThromboGenics for the six months ended June 30, 2018 (the 'interim period') include ThromboGenics NV and its subsidiaries ThromboGenics, Inc. and Oncurious NV, who constitute the ThromboGenics Group.

The condensed consolidated interim financial information does not include all the necessary information for preparing financial statements for a full accounting year and therefore should be read in conjunction with the annual financial statements of the group for the year ended December 31, 2017.

The condensed consolidated interim financial information of the Group was subject to a limited review by our statutory auditor but have not been audited.

The principal risks during the interim period have not materially changed from those mentioned in the financial report as of December 31, 2017.

All statements and information relate to the interim period unless otherwise stated.

The consolidated financial statements are presented in euro and all values are rounded to the nearest thousand except when otherwise indicated.



1.2. Accounting policies

The same accounting policies, presentation and methods of computation have been followed in these condensed financial statements as were applied in the preparation of the Group's financial statements for the year ended December 31, 2017, except for the potential impact of the adoption of the Standards and Interpretations described below.

New Standards, Interpretations and Amendments adopted by the Group

During the current financial period, the Group has adopted all the new and revised Standards and Interpretations issued by the International Accounting Standards Board (IASB) and the International Financial Reporting Interpretations Committee (IFRIC) of the IASB as adopted by the European Union and effective for the accounting year starting on January 1, 2018. The Group has not applied any new IFRS requirements that are not yet effective as per June 30, 2018.

The following new Standards, Interpretations and Amendments issued by the IASB and the IFRIC as adopted by the European Union are effective for the financial period and adopted by the Group:

- IFRS 2 Share-based Payment — Amendments to clarify the classification and measurement of share-based payment transactions (June 2016)
- IFRS 4 Insurance Contracts – Amendments regarding the interaction of IFRS 4 and IFRS 9 (September 2016)
- IFRS 9 Financial Instruments — Classification and Measurement (Original issue July 2014, and subsequent amendments)
- IFRS 15 Revenue from Contracts with Customers (Original issue May 2014 and subsequent amendments)
- IFRS 15 Revenue from Contracts with Customers – Clarifications (Original issue April 2016)
- IAS 28 Investments in Associates and Joint Ventures – Amendments resulting from Annual Improvements 2014-2016 Cycle (December 2016)
- IAS 39 Financial Instruments: Recognition and Measurement — Amendments for continuation of hedge accounting (fair value hedge of interest rate exposure) when IFRS 9 is applied (November 2013)
- IFRIC 22 Foreign Currency Transactions and Advance Consideration (December 2016)

IFRS 15 Revenue from Contracts with Customers

IFRS 15 Revenue from Contracts with Customers replaced all current revenue recognition requirements under IFRS. This standard provides in a five-step model that should be applied to all contracts with customers:
- Identify the contract with a customer;
- Identify the separate performance obligations in the contract;
- Determine the transaction price;
- Allocate the transaction price to the performance obligations;



- Recognize revenue when the performance obligation is satisfied;

Prior to adopting IFRS 15, collected payments from research milestones were considered as revenue upon payment. Under IFRS 15, revenue is only recognized at an amount that reflects the consideration to which the Group expects to be entitled in exchange for the satisfied performance obligation. A performance obligation is satisfied when the control of goods or services is transferred to a customer. Any upfront payments or license fees for which there are subsequent performance obligations, are initially reported as deferred revenue and are recognized as revenue when performance obligations are satisfied over the period of the development collaboration or manufacturing obligation.

The amount of revenue recognized is the amount allocated to the satisfied performance obligation taking into account variable consideration. The estimated amount of variable consideration is included in the transaction price only to the extent that it is highly probable that a significant reversal in the amount of cumulative revenue recognized will not occur and is estimated on the basis of historical experience and the specific terms in the individual agreements. A liability is recognized for expected sales returns, rebates, trade and cash discounts, charge-backs or other reimbursements payable directly or indirectly to customers in relation to sales made until the end of the reporting period.

Royalties are generated under license agreements based on licensee sales of products incorporating the Group's proprietary technology. Prior to adopting IFRS 15, royalties were recognized once the amounts due could be reliably estimated based on the sale of the underlying products and when collectability was assured. When the Group was unable to reliably estimate the royalty income due until receipt of the payment, the royalty income was accounted for as received rather than when due. Under IFRS 15, sales-based royalties resulting from the out-licensing of IP are recognized as the subsequent underlying sales occur provided that the related performance obligation has been satisfied by then. Any variable consideration that is promised in exchange of a license of IP and that is based upon achieving certain sales targets, is accounted for in the same way as sales-based royalties i.e. at the moment the related sales occur provided that the related performance obligation has been satisfied.

With respect to the sales of products, we concluded that there is no material difference in accounting treatment compared to the former standard. For this revenue stream, revenue will be recognized when control of the product is transferred to a customer.

The adoption of all other new standards and amendments has not led to major changes in the Group's accounting policies.

Standards and Interpretations issued but not yet effective in the current period

The Group elected not to early adopt the following new Standards, Interpretations and Amendments, which have been issued by the IASB and the IFRIC but are not yet effective as per June 30, 2018 and/or not yet adopted by the European Union as per June 30, 2018 and for which the impact might be relevant.



- Annual Improvements to IFRSs 2015-2017 Cycle (December 2017) *
- IFRS 9 Financial Instruments – Amendments regarding prepayment features with negative compensation (October 2017)
- IFRS 16 Leases (Original issue January 2016)
- IFRS 17 Insurance Contracts (Original issue May 2017) *
- IAS 19 Employee Benefits – Amendments relating to Plan Amendment, Curtailment or Settlement (February 2018) *
- IAS 28 Investments in Associates and Joint Ventures – Amendments regarding long-term interests in Associates and Joint-Ventures (October 2017) *
- IFRIC 23 Uncertainty over Income Tax Treatments (June 2017) *
- Amendments to References to the Conceptual Framework in IFRS Standards (March 2018) *

* Not yet endorsed by the EU as of June 30, 2018

The following new standards, interpretations and amendments, which have not been applied in these financial statements, will or may have an effect on the Group's future financial statements.

IFRS 16

IFRS 16 will be effective for annual periods beginning on or after January 1, 2019. The Group is currently in the process of capturing the relevant data needed under the new standard, in order to analyse and quantify the impact of adopting IFRS 16. Major leases are for offices, cars and some equipment. The Group has not yet decided on the transition approach to be used.

None of the other new standards, interpretations and amendments, which are effective for periods beginning after January 1, 2018 which have been issued by the IASB and the IFRIC but are not yet effective as per June 30, 2018 and/or not yet adopted by the European Union as per June 30, 2018, are expected to have a material effect on the Group's future financial statements.

1.3. Main accounting estimates and assessments

Preparing condensed consolidated interim financial statements in accordance with IFRS obliges the management to make estimates and assumptions that affect the reported amounts of assets, liabilities and the notes on the latent assets and liabilities on the date of the condensed consolidated interim financial statements, and the reported amounts of income and costs during the reporting period. If in the future such estimates and assumptions, which are based on management’s best estimates and judgment at the time of drawing up the financial statements, deviate from the actual circumstances, the original estimates and assumptions will be modified, and the effects of the revisions will be reflected in the period in which the circumstances change.



For information regarding our main accounting estimates and assessments, please see Note 5.5.4. to our 2017 consolidated financial statements included in our Annual Report, except in relation to revenue recognition, which is being replaced as a consequence of the adoption of IFRS 15 Revenue from Contracts with Customers:

Under the five step model established by the standard, the Group's main estimates and assessments relate to identifying the performance obligations that its contracts comprises and on the allocation of the transaction price according to the stand-alone selling price of each of the performance obligations.

The company sources of revenue are derived for the majority from sales of JETREA® vials through our US affiliate and from one distributor for ex-US. As sales are for one unique product and are happening at comparable conditions worldwide, no disaggregation is shown.

With respect to the determination of the transaction price and its allocation to the different performance obligations, the Group is using the stand-alone selling prices of the vials.

Step	Sale of vials
Performance obligations	Sale of goods to a third party. Returns credited strictly at discretion of ThromboGenics, provision for returns made on actual statistics
Performance timing	Sales to the distributor
Time	At sales to the distributor
Pricing	Stand-alone per vial
Combined Goods or Services	Not combined with other goods or Services

From September 15, 2018, as a result of the return of rights of JETREA® for selected markets, the Company will be working with additional licensees and distribution contracts. Compliance with IFRS 15 of these new contracts will be commented and reported in our 2018 annual report.

2. Result of the period

During the first six months of 2018, the income of ThromboGenics from commercial operations amounted to €3.8 million, this compared to a total income of €2.7 million in the first six months of 2017. Sales were relative to one drug product, JETREA®.
During the first six months of 2018, the Group reported a gross profit of €2.6 million, compared to a gross profit of €0.8 million in HY 2017.

ThromboGenics' R&D expenses were €13.3 million during the first half year of 2018, including an amortization on the intangible assets with regards to JETREA®'s Phase 3 program (in the VMA/VMT indication) of €1.6 million. In the same period of 2017, the R&D expenses were €10.5 million also including €1.6 million amortization expense. The increase in the total R&D expenses in 2018 is due to the start of new clinical studies for two of our pipeline compounds.



General and administrative expenses declined from €3.2 million to €2.9 million in the first half of 2018.

Selling expenses amounted to €2.5 million compared to €2.1 million in the corresponding period of 2017.
For the first half of 2018, ThromboGenics reported a net loss of €15.2 million (or €-0.39 per share). This compares with the corresponding period in 2017 when the company reported a net loss of €15.2 million (or €-0.42 per share).

3. Financial position and cash flow

The capitalized intangible assets mainly relate to JETREA®'s Phase 3 program amounting to €20.0 million and to €1.0 million for the exclusive in-licensing of the Galapagos NV compound at June 30, 2018. The change compared to the end of 2017 is due to amortization of €1.6 million in the first half-year.

As of June 30, 2018, ThromboGenics had €101.4 million in cash and investments (including investments representing €25.6 million). This compared to €115.7 million on December 31, 2017 (including €49.6 million of investments and €10 million of restricted cash).

The other reserves amount to €-13.2 million on June 30, 2018, which compares with €-13.1 million on December 31, 2017.

At the end of the first half-year of 2018, the total equity of ThromboGenics was €128.1 million versus €133.4 million at the end of 2017. This is composed of a loss of the period of €15.2 million and a capital increase of €10 million.

The investments are reported at fair value as per June 30, 2018 and December 31, 2017. The carrying value of the financial liabilities and other financial assets measured at amortized cost as per June 30, 2018 and December 31, 2017 approximate their fair value.

4. Capital structure and evolution of the equity

An effective capital increase of €10 million took place on January 5, 2018, with 2,177,226 new shares being delivered to Novartis Pharma AG, bringing the total number of shares on June 30, 2018 to 38,271,575 compared to 36,094,349 as per 31 December 2017, increasing the share capital with €9,796,303.31 and the share premium with €203,696.69.

On June 1, 2018, by decision of the extraordinary general shareholders meeting, accumulated losses of ThromboGenics NV were absorbed by reduction of share premium for an amount of €157,864,957.06 and a capital decrease for an amount of €24,302,544.14.



The capital and share premium changed as follows:

In '000 euro	Capital	Share premium
31 December 2017	151,991	157,661
Capital increase	9,796	204
Capital decrease	-24,302	-157,865
30 June 2018	137,485	0

The loss of the period was carried forward and brings the equity at €128.1 million on June 30, 2018.

In February 2018, warrants from the Warrant Plan 2017 have been granted to employees and consultants of the Group. The fair value of each warrant has been assessed on the basis of the Black-Scholes model on the date it is granted taking into consideration the same assumptions as used at year-end 2017.

5. Key agreements, commitments and contingent liabilities

Interest-bearing loans
The Group has not concluded any new credit agreements during the interim period.

Litigation
During the 1st half year of 2018, none of the ThromboGenics' entities were involved in a litigation.

Other Commitments
The Company has not concluded any new commitments that could influence substantially the financial position of the Company beside those mentioned in our latest annual report.

For the risks and the uncertainties for the rest of the year, we refer to the analysis included in the latest available Annual Report for 2017. No new elements of risk have been identified in the first six months of 2018 which require a modification of the list of risks and uncertainties.

6. Transactions with Related Parties

In the first 6 months of 2018, an amount of €293.3 thousand was paid to the executive directors.

No other transactions with related parties were made during the first 6 months of 2018 which have a material impact on the financial position and results of the Group. There were also no changes to related party transactions disclosed in the Annual Report 2017 that potentially had a material impact to the financial figures of the first 6 months of 2018.



7. Events occurring after the reporting period

On September 3, 2018, ThromboGenics held a second extraordinary general shareholders meeting to obtain approval of changing the name of ThromboGenics to Oxurion.

To date, no other events occurring after the half-year results as of June 30, 2018 are being evaluated as having an impact on the interim financial statements.

8. Segment reporting

An operational segment is a component of an entity:

- which exercises operating activities with which profits are being gained and with which costs can be made (including profits and costs from transactions with other components of the entity);
- of which the operational results are being judged regularly by the highest function of the entity who can take important operational decisions (Chief operating decision maker) in order to make decisions regarding the granting of resources and to evaluate the financial results of the segment; and
- for which separate financial information is available that is engaged either in providing specific products or services (business segment), or in providing products or services within a particular economic environment (geographical segment), which is subject to risks and rewards that are different from those of other segments.

ThromboGenics considers itself an integrated R&D and commercial Biotech company and reports its activities in only one general segment.

9. General information

ThromboGenics NV ("the Company") was incorporated on May 30, 2006 and is a limited liability company (in Dutch: naamloze vennootschap). The registered office is established at:

Gaston Geenslaan 1
3001 Leuven
Belgium
Tel: +32 (0)16 751 310
Fax: +32 (0)16 751 311

The company is registered in the Crossroads Databank for Enterprises under single business number 0881.620.924.

ThromboGenics is listed on Euronext Brussels. ThromboGenics is a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines for the treatment of eye diseases. The Company's lead product is JETREA® which was granted approval by the US Food and Drugs Administration (FDA) on October 18, 2012, for the treatment of symptomatic vitreomacular



adhesion (VMA), otherwise indicated as vitreomacular traction (VMT). On January 14, 2013, JETREA® was launched in the US by its own sales and marketing team within its subsidiary ThromboGenics, Inc.

On March 15, 2013, the European approval of the European Commission followed.

In March 2012, ThromboGenics signed a strategic partnership deal with Alcon (Novartis) for the commercialization of JETREA® outside the US. Under this agreement ThromboGenics has received €75 million in 2012 and €90 million in 2013. The contractual arrangement with Alcon (Novartis) was terminated effective September 15, 2017.

On April 3, 2015, ThromboGenics founded a subsidiary, Oncurious NV, which has the rights to TB-403 and together with VIB ("Vlaams Instituut voor Biotechnologie"), will develop this potential oncology therapy.

On September 3, 2018, ThromboGenics will hold a second extraordinary general shareholders meeting to obtain approval of changing the name of ThromboGenics to Oxurion.

The consolidated financial statements of the Group for the year 2017 are available on request at the above-mentioned address or on the Company's website (http://www.thrombogenics.com/investors/reports-presentations).



ThromboGenics
Advancing Science. Enhancing Vision.

Declaration of responsible persons

Patrik De Haes, Chief Executive Officer and Dominique Vanfleteren, Chief Financial Officer of ThromboGenics declare that, as far as they are aware:

- The condensed consolidated interim financial statements, made up according to the applicable standards for financial statements, give a true and fair view of the equity, financial position and the results of the Company and its consolidated companies.

- This interim report represents a true and fair view of the development and the results of the company for the first 6 months of 2018, and of the principal risks and uncertainties for the second half year and of the transactions with related parties.